ARTICLE | Clinical News
P54: Began Phase II testing
February 12, 2001 8:00 AM UTC
Phytopharm plc (LSE: PYM), Godmanchester, U.K. Product: P54 Business: Autoimmune/Inflammation Therapeutic category: NSAID Target: Cyclo-oxygenase 2, inducible nitric oxide synthase Description: Combi...